PT - JOURNAL ARTICLE AU - Grant A Mackenzie AU - Jessica McLellan AU - Eunice Machuka AU - Malick Ndiaye AU - Jayani Pathirana AU - Augustin Fombah AU - Baderinwa Abatan AU - Ilias Hossain AU - Ahmed Manjang AU - Brian Greenwood AU - Philip C Hill TI - Aetiology of Lobar Pneumonia Determined by Multiplex Molecular Analyses of Lung and Pleural Aspirate Specimens in The Gambia AID - 10.1101/2021.07.02.21259855 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.02.21259855 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259855.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259855.full AB - Background Pneumonia aetiology generally relies on insensitive blood cultures or an assumption that organisms in the pharynx are causal. We determined the causes of lobar pneumonia in rural Gambia using lung aspiration.Methods Pneumonia surveillance was undertaken among all ages. Blood culture and chest radiographs were performed routinely while lung or pleural aspirates were collected from selected patients. 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in August 2009 and replaced by PCV13 from May 2011. We used conventional microbiology, and from April 8, 2011 to July 17, 2012, utilized a multiplex PCR assay on lung aspirates. We calculated proportions with pathogens, associations between co-infecting pathogens, and PCV effectiveness.Results 2,550 patients were admitted with clinical pneumonia; 741 with lobar pneumonia or pleural effusion. We performed multiplex PCR on 156 lung and 4 pleural aspirates. Pathogens were detected in 116 specimens, Streptococcus pneumoniae (n=68), Staphylococcus aureus (n=26), and Haemophilus influenzae type b (n=11). Bacteria (n=97) were more common than viruses (n=49). Common viruses were bocavirus (n=11) and influenza (n=11). Co-infections were frequent (n=55). M. catarrhalis was detected in eight patients and in every case there was co-infection with S. pneumoniae. The odds ratio of vaccine-type pneumococcal pneumonia in patients with two or three compared to zero doses of PCV was 0.17 (95% CI 0.06, 0.51).Conclusions Lobar pneumonia in rural Gambia was caused primarily by bacteria, particularly S. pneumoniae and S. aureus. Co-infection was common and M. catarrhalis always co-infected with S. pneumoniae. PCV was highly efficacious against vaccine-type pneumococcal pneumonia.What is the key question?Using specimens directly from the infected lung, what is the aetiology of lobar pneumonia in rural West Africa?What is the bottom line?Using specimens directly from the infected lung, Streptococcus pneumoniae and Staphylococcus aureus were the predominant causes of lobar pneumonia in rural West Africa and pneumococcal conjugate vaccine effectively prevented pneumococcal pneumonia.Why read on?Learn about the certain aetiology of lobar pneumonia in 160 Gambian patients with specimens directly from the lung.Competing Interest StatementFunding payments for research were received by the Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine from the Bill and Melinda Gates Foundation.Clinical TrialThis is an observational study.Funding StatementThis work was supported by the Bill & Melinda Gates Foundation [grant number OPP1020327] and the Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted for the study by the Gambia Government/Medical Research Council (UK) Joint Ethics Committee (numbers 1087 and 1247). Written informed consent was obtained from patients or guardian for all study procedures.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the MRCG Scientific Coordinating Committee and Gambia Government/MRCG Joint Ethics Committee. Deidentified patient data may be requested from the MRCG Data Management and Archives department.